At Detroit Life Sciences, we are redefining the standards of intravenous therapy through innovation, precision, and purpose. As a leader in the global IV solutions market projected to reach over $23 billion by 2033, we are committed to delivering advanced, patient-centric solutions that address the world’s most pressing healthcare challenges.

To enhance patient outcomes by developing and delivering high-quality intravenous solutions that support critical care, chronic disease management, and nutritional therapy across diverse healthcare settings.

To manufacture injectable products using high-throughput platforms, reducing time and cost for products focused on unmet medical needs.

Detroit Life Sciences, LLC is a subsidiary of Shamekh IV Solutions. It was founded to bring back pharmaceutical manufacturing to the U.S. and allied regions. The facility is designed to meet U.S. and international regulatory standards while fostering public health, economic growth, and supply chain resilience.

We partner with global leaders like ICU Medical, Otsuka Pharmaceutical, and Intellego Technologies to strengthen supply chains, accelerate innovation, and ensure safety in IV therapy. Our commitment to R&D drives the development of next-generation formulations tailored to pediatric, geriatric, and critical care needs.

With a strong presence across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, we are addressing regional healthcare demands through scalable manufacturing, regulatory excellence, and localized partnerships.

Our solutions are trusted in hospitals, ICUs, outpatient clinics, and home care environments—empowering healthcare providers to deliver hydration, nutrition, and medication with unmatched precision.